A multinational, multicenter, randomized, double-blind, parallel group, placebo controlled clinical trial of the effects of tibolone (Org OD-14 1.25mg) on the incidence of new vertebral fractures in osteoporotic postmenopausal women.

Trial Profile

A multinational, multicenter, randomized, double-blind, parallel group, placebo controlled clinical trial of the effects of tibolone (Org OD-14 1.25mg) on the incidence of new vertebral fractures in osteoporotic postmenopausal women.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Feb 2017

At a glance

  • Drugs Tibolone (Primary)
  • Indications Fracture; Postmenopausal osteoporosis; Vertebral fracture
  • Focus Therapeutic Use
  • Acronyms LIFT
  • Sponsors Merck Sharp & Dohme; Organon
  • Most Recent Events

    • 07 Oct 2009 Additional lead trial centre and sponsor (Schering-Plough) identified as reported by ClinicalTrials.gov.
    • 07 Oct 2009 Planned number of patients (4534) added as reported by ClinicalTrials.gov.
    • 07 Oct 2009 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top